论文部分内容阅读
目的:观察新型中药复方制剂心康口服液预防和治疗柯萨奇B3（CVB3m）感染小鼠急性病毒性心肌炎形态学及形态定量学改变的作用。方法:将小鼠随机等分为模型组、阳性药（干扰素、Ribavilin）对照组、心康口服液组及正常对照组,并腹腔接种CVB3m病毒液建立病毒性心肌炎模型。预防组在用药2d后建立病毒性心肌炎模型,连续用药20-22d,观察比较第5、10和20d小鼠心脏肉眼及组织形态学改变并进行形态定量学测量,所得数据用SPSS/PC软件包作统计学处理。结果:心康口服液中、小剂量组及干扰素组第20d时心脏表面重度病变检出率与病毒组有显著意义P<0.01;心肌组织重度损伤（心肌细胞大片坏死崩解）检出率第20d时均低于病毒感染对照组、Ribav-ilin对照组及干扰素对照组,其中,中、小剂量组与病毒组有显著意义P<0.01;心肌病变面积/全心面积比值第10d及20d时心康口服液中、小剂量组及干扰素对照组与病毒对照组有显著意义P<0.01;平均病变面积预防用药第10d及20d,治疗用药第20d心康口服液中、小剂量组及干扰素组与病毒感染对照组有显著意义P<0.01。结论:心康口服液对CVB3m病毒感染小鼠的预防性及治疗性给药可保护心肌,减轻心肌损伤及促进损伤心肌修复,其预防作用类似干扰素,治疗作用优于Ribavilin,预防用药疗效较治疗用药为好?
OBJECTIVE: To observe the effects of Xinkang Oral Liquid, a new Chinese compound preparation, on the prevention and treatment of acute viral myocarditis in mice infected with Coxsackie B3 (CVB3m). METHODS: Mice were randomly divided into model group, positive drug (interferon, Ribavilin) control group, Xinkang oral liquid group and normal control group. Viral myocarditis model was established by intraperitoneal injection of CVB3m virus. In the prevention group, the viral myocarditis model was established after 2 days of drug administration. Drugs were continuously administered for 20-22 days. The visual and histological changes of the hearts of the 5th, 10th and 20th mice were compared and morphometric measurements were performed. The data obtained were analyzed using SPSS/PC software package. For statistical processing. RESULTS: The detection rate of severe heart disease on the 20th day in Xinkang Oral Liquid, small-dose group and interferon group was significantly different from that in the virus group (P<0.01). The detection rate of severe myocardial tissue damage (myocardial cell necrosis and disintegration) was significant. At the 20th day, they were all lower than the virus infection control group, Ribav-ilin control group and interferon control group. Among them, there was significant difference between medium and small dose group and virus group (P<0.01), and the ratio of myocardial lesion area/total heart area ratio was 10d and 20d Shixinkang oral medium, small dose group and interferon control group and virus control group had significant significance P<0.01; average lesion area prevention medication on the first 10d and 20d, treatment medication 20d Xinkang oral medium and small dose group There was a significant difference between the interferon group and the virus infection control group (P<0.01). Conclusion: The preventive and therapeutic administration of Xinkang Oral Liquid to CVB3m virus-infected mice can protect myocardium, reduce myocardial injury and promote repair of damaged myocardium. Its preventive effect is similar to that of interferon, and its therapeutic effect is better than Ribavilin. Treatment of drugs is good?